A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Clinical trial NCT03852251 · COMPLETED

Trial details

NCT number: NCT03852251
Sponsor: Akeso
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Gastric Adenocarcinoma Advanced Solid Tumors Gastroesophageal Junction Adenocarcinoma

Start date: 2019-01-18
Primary completion: 2024-03-25
Enrollment: 338

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.